A major development in the field of genomics has been announced, as Integrated DNA Technologies (IDT), a Danaher company and a global leader in the sector, has activated a strategic collaboration with Profluent Bio, a leader in AI-first protein design. This partnership is centered on combining their respective strengths to design and optimize next-generation enzymes.

This partnership unites Profluent’s cutting-edge generative AI platform, which includes foundational models like ProGen3 trained on the curated Profluent Protein Atlas, with IDT’s established expertise in enzymology, genomics, and global manufacturing capabilities.

The core objective is to move beyond the constraints of natural evolution by integrating AI-driven protein design, thereby unearthing new possibilities for novel enzyme variants and unlocking step-changes in enzyme efficiency, precision, and manufacturability. This strategic move also strengthens IDT’s recently established innovation nexus in the Bay Area, signaling its commitment to pioneering synthesis technologies and accelerating growth in areas like oncology research.

IDT will leverage its infrastructure to test, validate, and scale the Profluent-designed sequences, which will fuel its new product innovation pipeline. The resulting highly precise and customized enzymology capabilities are set to enhance IDT's offerings across a broad range of critical applications, including epigenetics, cancer research, next-generation sequencing, synthetic biology, and gene editing, ultimately streamlining the path from in silico designs to ready-to-use biological tools with enhanced speed, scale, and scientific impact.